These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 32671601)

  • 1. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
    Talasaz AH; Kakavand H; Van Tassell B; Aghakouchakzadeh M; Sadeghipour P; Dunn S; Geraiely B
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):249-259. PubMed ID: 32671601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac Involvement of COVID-19: A Comprehensive Review.
    Chang WT; Toh HS; Liao CT; Yu WL
    Am J Med Sci; 2021 Jan; 361(1):14-22. PubMed ID: 33187633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era.
    Ceriello A; Standl E; Catrinoiu D; Itzhak B; Lalic NM; Rahelic D; Schnell O; Škrha J; Valensi P;
    Diabetes Care; 2020 Jul; 43(7):1427-1432. PubMed ID: 32409501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment.
    Luo J; Zhu X; Jian J; Chen X; Yin K
    Acta Biochim Biophys Sin (Shanghai); 2021 Mar; 53(3):273-282. PubMed ID: 33428706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine.
    Davoudi F; Miyashita S; Yoo TK; Lee PT; Foster GP
    Crit Pathw Cardiol; 2022 Sep; 21(3):123-129. PubMed ID: 35994720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular implications of SARS-CoV-2 infection: A literature review].
    García-Saavedra MB; Rosales-Gutiérrez RR; Valverde E; Chumbes-Aguirre M; Alvarado R; Polo R; Azañero R; Chávez C
    Medwave; 2020 Aug; 20(7):e8008. PubMed ID: 32877391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latin-American Registry of Cardiovascular Disease and COVID-19: Rationale and Design of the CARDIO COVID 19-20 Registry.
    Gómez-Mesa JE; Galindo-Coral S; Montes MC; Alarco W; Barisani JL; Magaña A; Perna ER; Romero A; Speranza M; Mendoza I; Wyss F
    Glob Heart; 2021 Feb; 16(1):14. PubMed ID: 33833938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations.
    Wang RS; Loscalzo J
    Circ Res; 2023 May; 132(10):1374-1386. PubMed ID: 37167362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Overview on COVID-19 and its Effect on Cardiovascular Diseases.
    Hamadi A; Mahzari A; Hakami A; Hindawi S; Dobie G; Sayyed MI; Hamdi F; Nahari M; Jackson DE
    Endocr Metab Immune Disord Drug Targets; 2021; 21(11):1949-1953. PubMed ID: 33371840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular aspects of COVID-19.
    Kurz DJ; Eberli FR
    Swiss Med Wkly; 2020 Dec; 150():w20417. PubMed ID: 33382450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular manifestations of COVID-19: An evidence-based narrative review.
    Sharma YP; Agstam S; Yadav A; Gupta A; Gupta A
    Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):7-16. PubMed ID: 33818464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports.
    Soumya RS; Unni TG; Raghu KG
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):411-425. PubMed ID: 32926272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous Thromboembolic Disease in COVID-19, Pathophysiology, Therapy and Prophylaxis.
    Dybowska M; Wyrostkiewicz D; Opoka L; Lewandowska K; Sobiecka M; Tomkowski W; Szturmowicz M
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.
    Moirangthem DS; Surbala L
    Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.
    Ogah OS; Umuerri EM; Adebiyi A; Orimolade OA; Sani MU; Ojji DB; Mbakwem AC; Stewart S; Sliwa K
    Glob Heart; 2021 Mar; 16(1):18. PubMed ID: 33833942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular manifestations and treatment considerations in COVID-19.
    Kang Y; Chen T; Mui D; Ferrari V; Jagasia D; Scherrer-Crosbie M; Chen Y; Han Y
    Heart; 2020 Aug; 106(15):1132-1141. PubMed ID: 32354800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science.
    Evans PC; Rainger GE; Mason JC; Guzik TJ; Osto E; Stamataki Z; Neil D; Hoefer IE; Fragiadaki M; Waltenberger J; Weber C; Bochaton-Piallat ML; Bäck M
    Cardiovasc Res; 2020 Dec; 116(14):2177-2184. PubMed ID: 32750108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cardiac Effects of COVID-19: Review of articles.
    Niazi S; Niazi F; Doroodgar F; Safi M
    Curr Probl Cardiol; 2022 Feb; 47(2):100981. PubMed ID: 34534589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.
    Kumar D; Trivedi N
    Biomed Pharmacother; 2021 Jul; 139():111642. PubMed ID: 33940506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.